While the TNM staging system in combination with molecular markers (RAS, BRAF, MSI) is the backbone of therapeutic decisions and used as a guideline for survival estimates, there is a wide variation in prognosis among CRC patients with the same TNM stage and a survival paradox of stage II/III CRC patients on account of the inherent heterogeneity that traditional clinicopathological and molecular features fail to explain. Here, BRAF is linked to colorectal carcinoma.